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appear to be little likelihood that the small quantities of
lanthanum absorbed with therapeutic doses of lanthanum
carbonate will lead to lysosomal overload and toxicity.
Extensive preclinical and clinical safety testing supports this
conclusion.
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In a letter to the editor, Damment1 from Shire Pharma-
ceuticals has questioned the interpretation of the results
from our recently published study in this journal.2 We
looked at the tissue accumulation of lanthanum in kidney,
bone, and liver from normal and uremic lanthanum-
treated rats. In Damment’s letter, he suggests that the only
appropriate comparison is the one between the lantha-
num-treated normal and lanthanum-treated uremic rats.
When looking at tissue accumulation, the appropriate
control for lanthanum-treated uremic rats is untreated
uremic rats. When we made this comparison, we demon-
strated a progressive accumulation of lanthanum in liver
over the entire course of the study. We also observed that
uremia enhances the accumulation of lanthanum as has
been shown by other investigators.3,4 In his letter,
Damment includes a graph showing that lanthanum
accumulation reaches steady-state conditions in longer
term studies. This study, however, was not performed in
uremic rats, but in normal animals. As with Damment’s
study, we also saw that lanthanum accumulation in liver
begin to plateau in lanthanum-treated normal rats.2
Lanthanum, however, will not be prescribed to normal
individuals; thus, these results have no relevance for
hemodialysis patients. On the other hand, Bervoets et al.3
showed significantly greater gastrointestinal absorption of
lanthanum in renal failure. This explains why we see a
greater and progressive accumulation of lanthanum in the
uremic state. Initial concern for lanthanum use had
centered around its potential effects on bone and brain,
as these were the tissues adversely affected by aluminum-
containing phosphate binders.5 We state in our paper that
lanthanum likely has no effect on either of these tissues or
for that matter, kidney. Given the experience with
aluminum-containing phosphate binders, we must be
certain that treatments designed to benefit our patients
will not, in fact, harm them. The jury is still out.
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To the Editor: The hemodialysis clearance calculators
developed by Walther et al.1 are a commendable initiative.
However, we wish to draw attention to their limitations for
modelling acute renal replacement therapy in the intensive
care unit. Like Michael’s equation, Dr Addis’ hemodialyzer
clearance (Kd) calculator assumes a fixed configuration for
blood flow (QB) and dialysate flow (QD) within the
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Figure 1 | Long-term liver lanthanum exposure. Liver lanthanum
concentrations in rats treated for 1 day, or 4, 12, 26, or 78 weeks with
1500–2000 mg/kg lanthanum carbonate, 13–17 times the human
dose of 3 g/day of elemental lanthanum. Values are the median and
25th/75th percentiles, n¼ 4–12 rats per time point. Data on file at
Shire Pharmaceuticals Inc., in preparation for publication.
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hemodialyzer, and a constant hemodialyzer mass transfer
coefficient (KoA) over a wide range of hemodialysis
operating conditions.2 When QB and QD are low, however,
mismatch of these flows within the hemodialyzer creates a
shunt in which no solute transfer occurs. In a previous study
of nine patients during sustained low-efficiency dialysis, QB
of 200 ml/min and QD of 100 ml/min were used with a 1.8 m2
polysufone low-flux hemodialyzer.3 Measured Kd for urea by
direct dialysis quantification averaged 77.9 ml/min, as
opposed to B100 ml/min predicted by both Michael’s
equation and Dr Addis’ calculator. Hemodialyzer KoA during
sustained low-efficiency dialysis averaged only 203.2 ml/min,
much lower than the manufacturer’s value. Such errors in
calculated Kd are important as they lead directly to
misleading solute time–concentration profiles in Dr Conlon’s
dialysis simulation spreadsheet, which does not iteratively
recalculate solute generation rate and volume of distribution
to offset input error.4 Finally, critically ill patients with acute
kidney injury are seldom in solute steady state;5 this
assumption underpins Dr Conlon’s dialysis simulation
spreadsheet and is unrealistic. In summary, the calculators
by Walther et al.1 are useful for stable patients with end-stage
kidney disease, but are less suited for modelling acute renal
replacement therapy in the intensive care unit.
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We are grateful to Drs Marshall and Golper1 for pointing
out that when flows are low, dialyzers may not achieve the
clearance rates predicted from values for KoA that are
derived from clearances measured at higher flows. We
should have noted in addition that clearances in vivo are
often lower than those predicted from manufacturers’ KoA
values, which are usually derived from clearance experi-
ments performed with saline solutions. An even greater
problem is that KoA values are usually available only for
urea, creatinine, and vitamin B12, and must be guessed at
for other solutes of interest. We disagree somewhat with
Drs Marshall and Golper about the application of the
models to acute renal failure. We should emphasize that it
is only the downloadable format, and not the theoretical
content, of our models that is new. Like other theoretical
models, they can predict plasma solute concentrations only
when solute production rates, solute distribution volumes,
and residual renal function are specified, and these latter
parameters are both variable and hard to estimate in
acutely ill patients. But we think that the models can still
be useful in helping nephrologists to think about solutes
other than urea. An example may be provided by the
description of sustained low-efficiency dialysis with QB of
200 ml/min and QD of 100 ml/min to which Marshall and
Golper refer.2 If urea is the only solute considered, the
predicted clearance is not much different for QB of 200 ml/
min and QD of 100 ml/min as compared to QB of 100 ml/
min and QD of 200 ml/min. But the models predict that the
clearance of solutes, which bind to plasma proteins, will be
higher using QB of 100 ml/min and QD of 200 ml/min.
3 We
think it is wrong to assume that all uremic toxins behave
like urea, and that modeling the effect of renal replacement
therapies on other classes of solutes may thus have some
value.
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Hardy–Weinberg equilibrium and
control subjects
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To the Editor: Consider a gene locus with two alleles, ‘A’ and
‘a’. The frequency of allele ‘A’ will be designated by p and that
of allele ‘a’ by q. Hardy and Weinberg showed that in a very
large population with random mating, the frequencies of AA,
Aa, and aa genotypes are p2, 2pq, and q2, respectively. The
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